DXSP DXS International PLC

Director/PDMR Shareholding

Director/PDMR Shareholding

DXS INTERNATIONAL PLC

(AQSE: DXSP)

Notification of Director / PDMR Dealing

DXS INTERNATIONAL PLC

The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 13 February, Mr Bob Sutcliffe, the Chairman, purchased 30,000 Ordinary Shares in the Company at a price of 2.89p per share.

Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,333.756 Ordinary Shares representing 2.08% of the issued share capital of the Company.

1



 
Details of the person discharging managerial responsibilities / person closely associated
a)



 
Name



 
Mr. Robert Sutcliffe



 
2Reason for the notification
a)



 
Position/status



 
Chairman
b)



 
Initial notification /Amendment



 
Initial
3



 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



 
a)



 
Name



 



 
DXS INTERNATIONAL PLC
b)



 
LEI



 



 
2138001R1KEUWTXEVJ44
4



 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)



 



 



 



 

















Description of the financial instrument, type of instrument Ordinary Shares of 0.33p each
  
Identification code ISIN GB00B2Q6HZ92
  
b)



 
Nature of the transaction



 
Purchase of shares
c)



 



 



 



 











Price(s) and volume(s)    
   Price(s) Volume(s) 
   2.89p





30,000





 
d)



 



 



 



 



 



 





























Aggregated information 
  
- Aggregated volume 
  
- Price 
  
e)



 
Date of the transaction



 



 
13 February 2025
f)



 
Place of the transaction



 



 
Aquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman

DXS International plc

-systems.com





01252 719800
AQSE Corporate Broker and Corporate Advisor

Hybridan LLP

Claire Louise Noyce
020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.



EN
14/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DXS International PLC

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Research: DXS International plc: Experts to Decide

DXS’s ExpertCare, a digital solution platform, is selected for the Grow Digital Health Midlands Programme. This Programme is a collaboration between Health Innovation East and West Midlands, to provide a platform to encourage digital innovation to address the NHS most pressing challenges. DXS will be exposed to the largest NHS England region, encompassing 11 Integrated Care Systems, and a population of approximately 11.8m people. The programme is designed to help UK technology innovators scale p...

 PRESS RELEASE

Company Update

Company Update DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare selected for prestigious Grow Digital Health Midlands Programme DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to announce that ExpertCare, its digital medicine solution, has been selected for the prestigious Grow Digital Health Midlands Programme. Grow Digital Health Midlands - a new collaboration from Health Innovation East Midlands and Health Innovation West Midlands, has announced its first cohort of nine high-potential digital health companies of which DXS and the ...

 PRESS RELEASE

Statement re Grant of Options and Warrants

Statement re Grant of Options and Warrants DXS INTERNATIONAL PLC (AQSE: DXSP) Granting of Share Options and Warrants The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, announces that it yesterday granted share options to a number of directors, employees, and consultants. Most of these options grants are under an Enterprise Management Incentive (“EMI”) scheme and the remainder under an unapproved share option scheme. All these Share Options are at an exercise pric...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 13 February, Mr Bob Sutcliffe, the Chairman, purchased 30,000 Ordinary Shares in the Company at a price of 2.89p per share. Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,333.756 Ordinary Shares representing 2.0...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 31 January, Mr Bob Sutcliffe, the Chairman, purchased 30,000 Ordinary Shares in the Company at a price of 2.89p per share. Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,303.756 Ordinary Shares representing 2.04...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch